With growing evidence supporting their benefits, SGLT2 inhibitors are now used not only in the treatment of T2DM but have also been integrated into several clinical guidelines for treating cardiovascular diseases—particularly heart failure—and CKD (Group KDIGOKCW, 2024; Author Anonymous, 2024; Heidenreich et al., 2022). This evidence concerns the gene SLC5A2 and chronic kidney disease.